Sirolimus as an alternative treatment in patients with granulomatous ‐lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells

ConclusionsThese two cases provide insight into the underlying local and systemic immune anomalies involved in the development of GLILD, including the possible role of Tregs. Combined chemotherapy is commonly used as treatment for GLILD when steroids fail, but there have been some reports of successful monotherapy. As far as we know, these are the first 2 GLILD patients treated successfully with sirolimus, suggesting the advisability of further study of mTOR inhibitors as a more targeted treatment for GLILD, if impairment in Tregs is demonstrated.This article is protected by copyright. All rights reserved.

Source: Pediatric Allergy and Immunology - March 1, 2018 Category: Allergy & Immunology Authors: Angela Dey à‐Martínez, Ana Esteve‐Solé, Natalia Vélez‐Tirado, Veronica Celis, Jordi Costa, Maria Cols, Cristina Jou, Alexandru Vlagea, Ana María Plaza‐Martin, Manel Juan, Laia Alsina Tags: Original Source Type: research